Abstract:Antagonizing angiogenesis-related receptor tyrosine kinase is a promising therapeutic strategy in oncology. In present study, we designed and synthesized a novel vascular endothelial growth factor receptor (VEGFR) inhibitor N-methyl-4-(4-(3-(trifluoromethyl) benzamido) phenoxy) picolinamide SKLB610 that potently suppresses human tumor angiogenesis. SKLB610 inhibited angiogenesis-related tyrosine kinase VEGFR2, fibroblast growth factor receptor 2 (FGFR2) and platelet-derived growth factor receptor (PDGFR) at rate of 97%, 65% and 55%, respectively, at concentration of 10 mu M in biochemical kinase assays. In vitro, SKLB610 showed more selective inhibition of VEGF-stimulated human umbilical vein endothelial cells (HUVECs) proliferation, and this proliferation inhibitory effect was associated with decreased phosphorylation of VEGFR2 and p42/44 mitogen-activated protein kinase (p42/44 MAPK). Antiangiogenic evaluation showed that SKLB610 inhibited the HUVECs capillary-tube formation on Matrigel in vitro and the sub-intestinal vein formation of zebrafish in vivo. Moreover, SKLB610 inhibited a panel of human cancer cells proliferation in a concentration-dependent manner and human non-small cell lung cancer cell line A549 and human colorectal cancer cell line HCT116 were most sensitive to SKLB610 treatment. In vivo, chronic intraperitoneally administration of SKLB610 at dose of 50mg/kg/d resulted in significant inhibition in the growth of established human A549 and HCT116 tumor xenografts in nude mice without exhibit toxicity. Histological analysis showed significant reductions in intratumoral microvessel density (CD31 staining) of 43-55% relative to controls depending on the specific tumor xenografts. In conclusion, the present study demonstrated that SKLB610 exhibited its antitumor activity as a multi-targeted inhibitor with more potent inhibition of VEGFR2 activity. Its potential to be a candidate of anticancer agent is worth being further investigated. Copyright (C) 2011 S. Karger AG, Basel

Supplementary Data from SKLB1002, a Novel Potent Inhibitor of VEGF Receptor 2 Signaling, Inhibits Angiogenesis and Tumor Growth in Vivo

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors

SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.

Sklb1002, A Novel Inhibitor of Vegf Receptor 2 Signaling, Induces Vascular Normalization to Improve Systemically Administered Chemotherapy Efficacy

Supplementary Figures 1-2 from Systemic Overexpression of Angiopoietin-2 Promotes Tumor Microvessel Regression and Inhibits Angiogenesis and Tumor Growth

Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

SKLB1002, a potent inhibitor of VEGF receptor 2 signaling, inhibits endothelial angiogenic function <i>in vitro</i> and ocular angiogenesis <i>in vivo</i>

Supplementary Legends 1-6 from Inhibition of MAPK Kinase Signaling Pathways Suppressed Renal Cell Carcinoma Growth and Angiogenesis in Vivo

Supplementary Figure 2 from Vasculostatin Inhibits Intracranial Glioma Growth and Negatively Regulates <i>in Vivo</i> Angiogenesis Through a CD36-Dependent Mechanism

SKLB-287, a Novel Oral Multikinase Inhibitor of EGFR and VEGFR2, Exhibits Potent Antitumor Activity in LoVo Colorectal Tumor Model.

Data from SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both <i>in Vitro</i> and <i>in Vivo</i>

YLT192, a Novel, Orally Active Bioavailable Inhibitor of VEGFR2 Signaling with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models

Supplementary Figures 1-3 from OSI-930: A Novel Selective Inhibitor of Kit and Kinase Insert Domain Receptor Tyrosine Kinases with Antitumor Activity in Mouse Xenograft Models

Supplementary Figure 6 from ASC-J9 Suppresses Renal Cell Carcinoma Progression by Targeting an Androgen Receptor–Dependent HIF2α/VEGF Signaling Pathway

Supplementary Data from &Lt;i>n<sup>6</sup></i>-Methyladenosine Promotes Translation of VEGFA to Accelerate Angiogenesis in Lung Cancer

Supplementary FIgure Legends from ASC-J9 Suppresses Renal Cell Carcinoma Progression by Targeting an Androgen Receptor–Dependent HIF2α/VEGF Signaling Pathway

Supplementary Figure 2 from Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma

Yl529, A Novel, Orally Available Multikinase Inhibitor, Potently Inhibits Angiogenesis And Tumour Growth In Preclinical Models

Supplementary Figure Legends from Lipoxin A4 and Its Analogue Suppress the Tumor Growth of Transplanted H22 in Mice: the Role of Antiangiogenesis

Legend for Supplementary Figures from Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma